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CHAPTER 1: INTRODUCTION
1.1 The Mitochondrion
Mitochondria are thread-like in appearance and contain an outer (OMM) and inner (IMM)
mitochondrial membrane (Figure 1). The double membranes form compartments within the
organelle structure: the intermembrane space (IMS) located between the membranes and the
matrix, sequestered by the IMM. The IMM is responsible for the formation of the mitochondrial
cristae, which are folds within the membrane, one of the hallmarks of mitochondrial morphology.
They are dynamic organelles, which can combine to exchange contents and the separate through
processes called fusion and fission (1). Mitochondria perform the critical function of aerobic
respiration, generating most of the energy required to sustain life. As studies of the mitochondria
progressed through out time, it was shown that they are also key regulators of the apoptosis,
reactive oxygen species production, metabolic signaling, and calcium homeostasis (2).

Figure 1. Mitochondrial structure and landmarks. The mitochondrion organelle consists of two
membranes: the outer mitochondrial membrane (OMM) and the inner mitochondrial membrane (IMM). The
IMM has a unique combination of lipids, including cardiolipin, that fold into cristae where the electron
transport chain and MICOS complexes are located. The matrix (lumen) houses the mitochondrial genome,
protein translational machinery, and metabolic pathways such as the tricarboxylic acid (TCA) cycle. This
figure was obtained from Bornstein et. al., 2020 (3) with permission of the publisher (Elsevier).
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Mitochondria are different from other cellular organelles, as they contain their own genetic
material (mtDNA). The 16,569 bp genome was completely sequenced in 1987, revealing that
mtDNA contains genes for the 12s and 16s ribosomal subunits, 22 tRNAs, 13 of the electron
transport chain subunits for complexes III, IV and V (4), and more recently small peptides (5) and
RNAs (6). All genes contained within the genome are critical for mitochondrial function and
mutations or deletions have deleterious effects on cellular function which results in disease and
aging pathologies (7, 8).
It was first proposed in 1967 that the mitochondrion may originate from an endosymbiotic
relationship between bacterial and eukaryotic cells (9). Although very controversial at the time,
this theory is now widely accepted by the scientific community, as subsequent analysis showed
that the mitochondrial proteome and genome more closely resembles that of a prokaryotic lineage
(10-12). In fact, with the development of high throughput technologies, the lineages of both the
host eukaryote and the endosymbiotic proteobacterium were traced. These phylogenomic studies
revealed that the host eukaryote is closely related to Asgard superphylum (archaea), specifically
Lokiarhaeota (10, 11).
The debate in the scientific community is no longer if mitochondria originated from an
ancestral endosymbiotic relationship but focuses on the timing of the event. The hypotheses
within the field are divided into two extremes: “mitochondria-early” and “mitochondria-late.”
Mitochondria-early postulations center around the idea that the endosymbiotic relationship is one
of the first events, if not the event, leading to the evolution of modern eukaryotes (13).
Mitochondria-late hypotheses suggest that the endosymbiotic relationship did not occur until
ancestral cells began displaying eukaryotic characteristics (14-17). In either case, the fact remains
that the endosymbiotic relationship between prokaryotes and pre-modern eukaryotes allowed
modern eukaryotes to harness the capability of increased ATP production through aerobic
respiration.
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1.2 Mitochondrial Function
1.2.1 Oxidative phosphorylation
Mitochondria are well known as “the powerhouse of the cell”, a phrase that was coined by
Peter Siekevitz in the 1950s. The organelles earned this nickname because they produce most
of the energy required for cellular functions through the tricarboxylic acid (TCA) cycle and
oxidative phosphorylation (OXPHOS) (18). The process of OXPHOS occurs at the IMM via a
series of four multi-subunit protein complexes called the electron transport chain (ETC) and ATP
synthase (Figure 2). Subunits of theses complexes are encoded by both the nuclear and the
mitochondrial genomes.

Figure 2. The electron transport chain and ATP synthase. The electron transport chain and ATP
synthase are imbedded in the IMM. Substrates are fed from the TCA cycle to complexes I and II as electron
doners. Electrons are transferred via the Q cycle to complex III and are then shuttled to complex IV via
cytochrome c. Complex IV uses the electrons to ultimately convert oxygen to water. Hydrogen ions are
pumped from the matrix into the IMS as the electrons move down the chain, creating a proton gradient that
is utilized by ATP synthase to convert ADP to ATP. This figure was obtained from Nolfi-Donegan et. al.,
2020 (19) with the permission of the publisher (Elsevier).

Substrates generated by the TCA cycle, NADH and FADH2, donate a pair of electrons to
complexes I (NADH dehydrogenase) and II (succinate dehydrogenase), respectively. The
electron pair then enter the Q-cycle, where ubiquinone (CoQ) is reduced to ubiquinol (CoQH2)
which shuttles electrons to complex III (cytochrome c reductase or bc1 complex). Ubiquinol is
oxidized by complex III and one electron at a time is transferred from complex III by cytochrome

4

c (cytc). The reduced cytc shuttles an electron to complex IV (cytochrome c oxidase or COX),
where molecular oxygen binds and is reduced to water.
As the electrons travel down the ETC, complexes I, III, and IV pump protons from the
matrix across the IMM, allowing COX to reduce molecular oxygen to water while establishing an
electrochemical proton gradient in the IMS, which generates a mitochondrial membrane potential
(∆Y) (20). The ∆Y, along with the proton concentration (pH), creates the proton motive force (∆p)
that couples electron transfer/oxygen consumption and the activity of ATP synthase (19). ATP
synthase moves protons from the IMS back to the matrix during the process of converting ADP
to ATP, which cause ∆Y to dissipate. In situations where proton leak across the IMM occurs,
respiration becomes uncoupled, and uncoupling proteins shuttle protons back to the matrix, in an
attempt to control ATP production (19).
1.2.2 Cellular metabolism, signaling, and mitophagy
In addition to the production of life sustaining amounts of cellular energy, mitochondria
have been shown to participate in the synthesis of numerous biomolecules such as proteins, fatty
acids, heme, iron-sulfur clusters, lipids, nucleotides, and amino acids via numerous pathways
(Figure 3) (21). They also play key roles in the production of reactive oxygen species (ROS) and
ROS signaling, calcium buffering and signaling, apoptosis, and mitophagy.
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Figure 3. Metabolic pathways in the mitochondria. Yellow arrows indicate critical biosynthetic pathways,
red arrows indicate redox-sensitive enzymatic reactions. This figure was obtained from Ahn et., al., 2015
(21) with permission from the publisher (Springer Nature).

The electron transport chain is a point of ROS generation in the cell, which is usually
caused by electron leakage at complexes I and III (20). Free electrons can interact with oxygen,
creating the free radicals known as superoxide, hydroxyl radical, singlet oxygen, and peroxide,
which are highly reactive molecules (22-24). Under normal conditions a homeostatic amount of
ROS is required for physiological signaling; however, too much ROS causes damage to proteins,
lipids, and nucleic acids. An accumulation of ROS occurs when the ROS scavenging system is
overwhelmed or dysfunctional resulting in disease pathologies including cancers, neurological
diseases, diabetes, and organ failure (25).
Mitochondria also play a role in cytoplasmic calcium homeostasis. Mitochondria have two
pathways for calcium uptake: The mitochondrial calcium uniporter (MCU) and cation transport
and exchange channels (26, 27). Cytosolic calcium plays a role in apoptosis by inducing the
release of cytc into the cytosol via the formation of the mitochondrial permeability transition pore
through cristae remodeling (28, 29). Additionally, mitochondria can regulate calcium signaling
through their close interaction with the endoplasmic reticulum. Mitochondria-associated
membranes (MAMs) play numerous roles in metabolism and transport including cholesterol and
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ceramide biosynthesis, phospholipids, proteins, ions, and many metabolites (30). The exchange
of calcium between the ER and mitochondria affects OXPHOS and autophagy pathways as well.
MAM dysfunction has been associated with various diseases including cancers and
neurodegenerative diseases (31).
The mitochondrial membrane is made up of multiple lipids produced by the mitochondria
itself or imported from the ER (32). As mentioned above, it has been shown that the close
interaction with the ER at the MAMs allows for mitochondria and the ER to exchange lipids and
thereby regulate lipid homeostasis (33). Dysregulation of mitochondrial lipid homeostasis results
in stress signaling pathway activation of the mitochondrial and cytosolic unfolded protein
responses (UPRs), discussed in detail in the next section (34).
Metabolic and stress signaling through the mitochondria is paramount in cellular
homeostasis; however, there is a point at which mitochondrial damage and dysfunction is too
great to repair. When mitochondria are damaged beyond repair, they are cleared via a mitocentric form of autophagy (the process of removing protein aggregates, organelles, and other
contents of the cytoplasm), appropriately called mitophagy (35). During mitophagy, mitochondria
are targeted by the autophagosome through a specific set of proteins activated by stresses such
as an increase in ROS levels and disrupted membrane potential (36). One pathway by which
mitophagy can be induced is ubiquitin mediated, involving the ubiquitination of mitochondria (37).
The classical signaling pathway for ubiquitin mediated mitophagy is the PINK1/Parkin
pathway. Under normal physiological conditions, PINK1, a mitochondrial serine/threonine kinase,
is continuously imported and cleaved by the matrix protein peptidases (MPP) and subsequently
cleaved by presenilin-associated rhomboid like (PARL), a protease in the mitochondrial inner
membrane. (38, 39). Upon mito-specific stress activation, PINK1 blocks mitochondrial import by
accumulating on the OMM, which leads to autophosphorylation through dimerization of the protein
(40-42). PINK1 then activates Parkin (an E3 ubiquitin ligase) through phosphorylation, which
subsequently leads to OMM protein and cytosolic protein ubiquitination, fission, and recruitment
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of the autophagosome (42, 43). Defective mitophagy can be seen with aging, as well as cancers,
heart and liver diseases, and neurodegenerative disorders (44).
1.2.2.1 Mitochondrial unfolded protein response
The mitochondrial unfolded protein response (mtUPR) is a stress signaling pathway that
has recently emerged as important in protein homeostasis of the mitochondria (45, 46). The
purpose of this pathway is to activate transcription of protein folding chaperones (heatshock
proteins), proteases (YME1L1, LONP1, and CLPP), and other stress response proteins in the
nucleus to protect the mitochondria from proteotoxic stress (Figure 4) (46, 47). Numerous
stresses can trigger the mtUPR in addition to protein misfolding, including OXPHOS dysfunction
and ROS, membrane depolarization, mtDNA damage, and immune response activation (48). The
pathway has been well characterized in Caenorhabditis elegans (49, 50) and is now an emerging
field in mammalian mitochondrial biology (46) and disease associations (51).

Figure 4. Mitochondrial matrix and IMS UPR overview. This figure was obtained from Arnould et. al.,
2015 (52) with permission from the publisher (MDPI).
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A main regulatory pathway of protein homeostasis is through the ubiquitin-proteasome
system in the cytosol, both by degrading proteins on the OMM and by degrading proteins stuck
in the cytosol due to slowed or blocked import machinery (53-56). An additional pathway has been
identified to manage proteotoxic stress within the mitochondrion itself. In C. elegans, a
transcription factor called ATFS-1 has been shown to be a key player in mtUPR. Under normal
conditions, ATFS-1 is imported into the mitochondria; however, during stress, a portion of ATFS1 is trafficked to the nucleus, where it activates transcription of genes involved in the mtUPR (50).
In mammals, a transcription factor, ATF5, performs a similar role in mitochondrial-nuclear
crosstalk and can rescue mtUPR in ATFS-1 deficient worms (57). ATF5 was recently shown to
be transcriptionally activated by MNRR1 (58). More recently, compartment specific mtUPRs have
emerged as important pathways in regulating proteotoxic stress within the mitochondria (Figure
4) (52).
1.2.2.2 Apoptosis
Apoptosis is the result of a cell’s inability to overcome stress or damage while attempting
to repair itself after an insult. There are two pathways by which cell fate can be committed to
death: extrinsic apoptosis (relies on cell surface receptors) and intrinsic apoptosis (relies on the
involvement of mitochondria), although it is possible for the extrinsic pathway to trigger the
intrinsic pathway (59, 60). The first step in intrinsic apoptosis is the formation of mitochondrial
outer membrane pores (MOMPs) and the release of unphosphorylated cytc into the cytosol,
committing cell fate to death (Figure 5) (61). The interaction between cytc and Apaf-1 forms the
apoptosome, which in turn activates the caspase cascade (62). Caspase proteins, which are
cysteine proteases, become active upon cleavage downstream of apoptosome formation, which
begin to degrade cellular substrates, thereby playing the role of cell executioner (63).
The Bcl-2 family of proteins play a key role in regulating the first step of intrinsic apoptosis
at the mitochondrial outer membrane. The Bcl-2 family of proteins is divided into two sections
based on function: anti-apoptosis proteins (such as Bcl-xL) and pro-apoptosis proteins (Bax and
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Bak) (64). Under normal conditions, Bax localizes to the cytosol and Bak is inserted into the OMM,
where it interacts with the antiapoptotic protein Bcl-xL. At the induction of apoptosis, the
interaction between Bcl-xL and Bak is interrupted by other proapoptotic proteins, allowing for the
oligomerization of Bak and Bax at the OMM, an action which forms the MOMPs necessary for the
release of cytc (60, 65, 66).

Figure 5. Mitochondrial decisions in cell life and death. Under normal conditions, mitochondria actively
respire by the process of OXPHOS. However, during stress, cytc is de-phosphorylated and Bcl-xL fails to
prevent the oligomerization of Bak and Bax allowing the release of cytc to into the cytosol from the
mitochondrial IMS, committing cell fate to death. The apoptosome is formed through the interaction of Apaf1 and dephosphorylated cytc and activates caspases. This figure was obtained from Kalpage et. al., 2020
(62) with the permission of the publisher (Elsevier).

1.3 Complex IV: Cytochrome c oxidase
Complex IV, or cytochrome c oxidase (COX), is one of the mitochondrial components that
our lab studies. COX is the terminal enzyme of the ETC and is responsible for reducing oxygen
to water. Physiologically, the mammalian complex is a dimer, with each monomer composed of
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13 tightly bound subunits embedded in the IMM, an assembly supported by several crystal
structures resolved from COX in bovine heart (Figure 6) (67, 68). However, more recently,
monomeric crystal structures of COX were also published (69, 70) and monomeric COX was also
reported in a supercomplex (71). It is therefore possible that an equilibrium exists between dimeric
and monomeric COX, which could be subject to regulation. COX has been shown to be a tightly
regulated complex via the presence of tissue-, developmental-, or species- specific subunit
isoforms, small molecule interactions, reversible subunit phosphorylation, protein-protein
interactions, and supercomplex formation (67, 72, 73)

Figure 6. Crystal structure of bovine heart cytochrome c oxidase at 2.8 Å. A. Transmembrane view of
COX. B. View of COX from the intermembrane space. Each subunit and corresponding name are
represented by its unique coloring within each COX monomer. This figure was obtained from Yoshikawa
et. al., 2012 (74) with permission from the publisher (Elsevier).

Additionally, a 14th subunit has been proposed—NDUFA4—which was originally believed
to be a subunit of complex I (75, 76). A structural study showed that NDUFA4 appears to be a
subunit in the COX monomer, likely adding to the stability of the complex (76). NDUFA4 as part
of the COX monomer is located at the interface of the dimeric complex, where it would prevent or
interfere with dimer formation, which could be a reason that the protein was never detected in the
dimeric crystal structure while being identified as part of monomeric COX structure (76). The
validity of NDUFA4′s role as a true subunit has been questioned and it was argued that, because
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NDUFA4 may bind to both complexes I and IV and is not consistently found in COX preparations,
it may function as an assembly factor for the respirasome (77).
The three largest subunits are encoded by the mitochondrial genome whereas the other
subunits are encoded by the nuclear genome. Among the mitochondrial-encoded subunits,
subunits I and II contain the catalytic centers. The latter consist of metal centers that are involved
in the electron acceptance from complex III via cytc and the pathway of the electron through the
complex itself: electrons received from cytc first reach the CuA center in subunit II, are then
transferred to heme a in subunit I, and finally reach the heme a3-CuB site of subunit I, where
oxygen is reduced to water.
The biogenesis and maturation of COX is critical for its proper function. There are multiple
steps in this tightly regulated process: the insertion of metal groups in COX I and COX II, the
import and folding of nuclear encoded subunits, and the proper assembly of the subunits into the
complex. Over 30 auxiliary proteins are involved in the biogenesis of the core enzyme composed
of COX I, COX II, and COX III (78). The hypothesized assembly pathway favors a modular–linear
assembly, where subunits are first assembled into module intermediates and then these modules
are assembled into the COX monomer (Figure 7) (79, 80). The first step of monomer assembly is
the synthesis of mitochondrially encoded COX I, including the insertion of heme a, which is
followed by its association with the COX IV and COX Va module (79, 81). The COX II module,
which requires the insertion of the CuA center into the subunit before assembly can continue (8285), forms a complex intermediate with COX VIc, COX VIIb, COX VIIc, and COX VIIIa. The COX
III module consists of COX III, COX VIa, COX VIb, and COX VIIa. These modules are then
assembled in a linear fashion, upon which NDUFA4 interacts to assist in the stabilization of the
COX monomer (79).
Over the years, many diseases have been studied that are associated with defective COX
biogenesis, which often affect the brain, heart, and skeletal muscle (86-88). Most of these
diseases involve assembly factors, chaperones, and other regulatory proteins because COX
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biogenesis and activity are tightly regulated processes (89). Mutations in SCO1/SCO2 (83, 9093), COX10 (94, 95), COX15 (96), and SURF1 (82, 92, 97, 98) have all been associated with
COX dysfunction. Studies have also shown that mutations in members of the twin CX9C family,
of which our lab also studies, can affect COX activity and are associated with various diseases
including neurological disorders, cancers, and cardiomyopathy (see next section).
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Figure 7. Assembly of cytochrome c oxidase. The assembly of COX is thought to be both modular and
linear. Dark blue, mitochondrial encoded COX core subunits; light blue, nuclear encoded COX subunit;
purple, assembly factors; gray, unknown function. *, Twin CX9C protein. Gray dashed lines represent
assembly factor interactions. Black dashed lines represent subunit assembly. This figure was obtained from
Gladyck et. al., 2021 (99) with the permission of the publisher (MDPI).

1.4 Twin CX9C Proteins
1.4.1 Unique structure for non-classical mitochondrial import
The twin CX9C family of proteins is characterized by its unique repeated motif of two
cysteines separated by nine amino acid residues. This motif is found in the coiled-coil-helix-coiledcoil-helix (CHCH) domain, where pairs of cysteines form a helix turn helix fold by forming disulfide
bonds with one another (Figure 8) (100-102). This domain provides structural stability for the twin
alpha helices but also makes the proteins redox sensitive due to the reactive nature of cysteine
residues (101-104). Another family of proteins, called the “small Tim” proteins, contain a similar
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but shorter twin CX3C motif, and act as chaperones in the TIM22 pathway for insertion of proteins
into the IMS-facing side of the inner membrane (IM), an important role in mitochondrial function
(105).
The CHCH domain is important for the import of the proteins into the intermembrane space
(IMS) of the mitochondria. IMS import is facilitated through the Mia40/CHCHD4 redox mechanism
based on cysteine residues (106-109). Unlike matrix or inner-membrane-bound proteins, proteins
that use the Mia40 pathway do not require a mitochondrial-targeting sequence (MTS) precursor.
Import via Mia40 works through a disulfide relay system wherein Mia40 is anchored to the inner
mitochondrial membrane, facing into the IMS. In this system, CX9C proteins are brought into the
IMS from the cytosol via the translocase of the outer membrane (TOM) in a reduced, unfolded
state. The oxidized cysteine residues of Mia40 then form disulfide bridges with the cysteine
residues of the incoming twin CX9C protein. After further modification to the disulfide bridges, the
imported CX9C protein is released into the IMS and Mia40 is re-oxidized by Erv1 (108).
It is interesting to note that some twin CX9C proteins are predicted to have an MTS; these
include CHCHD1, MNRR1/CHCHD2, and CHCHD10. Such observations suggest that these
proteins can use the translocase of the inner membrane TIM/TOM import as an alternative route
or that they may be able to also localize to the mitochondrial matrix (or the inner mitochondrial
membrane). CHCHD1 has been identified as a mitochondrial ribosomal protein and therefore is
able to use its MTS to localize to the mitochondrial matrix to participate in protein translation (110).
A third possibility is that these pre-sequences are not functional since MNRR1/CHCHD2 has been
shown to localize to the mitochondria even after the removal of its MTS (Aras and Grossman,
unpublished data)(111).
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Figure 8. CHCH-domain structure of Mia40. Disulfide bonds represented in yellow. This figure was
obtained from Banci et. al., 2009 (104) with permission for use form the publisher (John Wiley and Sons).

1.4.2 The role of twin CX9C proteins in COX regulation
The first studies of this family of proteins took place in Saccharomyces cerevisiae, where
a detailed study found that 13 of the 14 yeast family members were conserved across species
(103). Subsequent research determined that family member proteins are important in COX
complex assembly and function (Figure 6), as well as for direct regulation of the oxidase (Table
1) (112-115). Many of the protein family members are also associated with various diseases,
although their mechanisms are not well understood in pathology (Table 2).
Table 1. Human proteins, yeast nomenclature, and function of twin CX9C proteins (99).
Human Protein

Yeast Protein

Function

COX17

Cox17p

COX copper chaperone

COX19

Cox19p

COX assembly

CMC1

Cmc1p

COX assembly

CMC2

Cmc2p

COX assembly

COA5

Pet191p

COX assembly
COX assembly

COA6

Coa6p

CHCHD7

Cox23p

COX assembly

CHCHD8

Coa4p

COX/complex III assembly/function

MNRR1/CHCHD2

Mix17p

Activity regulation

CHCHD10

Mix17p

Activity regulation

CMC4

Cmc4p

Unknown

COX VIb1

Cox12p

Subunit
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Table 2. COX-associated twin CX9C proteins and diseases (99).
Protein

Disease Association

Reference

COX17

COX17-null embryonic lethal in mice

(116)

COX19

None

CHCHD7
CMC1

Salivary gland pleiomorphic adenomas (benign)

(117)

Lung adenocarcinoma

(118)

Acute myeloid leukemia

(118)

None

CMC2

None

COA5

Hypertrophic cardiomyopathy

(119)

COA6

Hypertrophic cardiomyopathy

(120-122)

CHCHD8

MNRR1/CHCHD2

CHCHD10

CMC4
COXVIb1

None
Parkinson’s disease

(123)

Huntington’s disease

(124)

Lissencephaly

(125)

Breast cancer

(126, 127)

EGFR-positive non-small cell lung cancer

(128)

Hepatitis B or C virus associated hepatocellular carcinoma

(129)

Charcot Marie Tooth disease type 1A

(113)

Mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes (MELAS) disease

(58)

Spinal muscular atrophy, Jokela type

(130)

ALS and/or front temporal dementia

(131, 132)

Autosomal dominant mitochondrial myopathy

(133)

Lower motor neuron syndrome

(134)

Charcot-Marie-Tooth disease type 2

(135)

T cell leukemia with translocation (X:14)

(136-140)

Frataxin mRNA deficiency

(138)

COX deficiency/mitochondrial encephalomyopathy

(141, 142)

1.5 Mitochondrial Nuclear Retrograde Regulator 1 (MNRR1)
MNRR1 (also called CHCHD2) and its isoform CHCHD10 have a common ancestor in
yeast called Mix17p (formerly Mic17p), which was initially shown to localize to the nucleus (143).
However, as interest in IMS protein import increased, it was determined that Mix17p also localized
to the IMS via the Mia40/Erv1 pathway (144). In a screen looking to determine which CX9C
proteins affect OXPHOS in yeast, the knockdown of Mix17p resulted in the reduction of oxygen
consumption to approximately 50% of WT (103). The protein was later shown to be stresssensitive using agents that induce DNA replication distress, a stimulus that also led to the
characterization of changes in protein localization (145).
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Mix17p and MNRR1 have 36% sequence identity, with a centrally located hydrophobic
domain, which is largely conserved (Figure 9). This overlap suggests that the hydrophobic central
domain plays an important role in the function of the protein. Additionally, the cysteines in the
CHCH domain are conserved in the twin CX9C motif. MNRR1 and CHCHD10 have 56% sequence
identity, which suggests they may perform similar functions in cells. As in yeast, mammalian
MNRR1 was determined to affect OXPHOS in a computational screen coupled with functional
assays in human cell lines (146). MNRR1 is a stress-sensitive protein and displays dual
localization to the mitochondria and the nucleus (114, 147). During 20% oxygen tension growth
in cell culture, most cellular MNRR1 is in the mitochondria; however, at more physiological 4%
oxygen tension, MNRR1 levels rapidly turn over in the mitochondria and increase in the nucleus
during stalled protein translation experiments (114). Our lab has recently shown that at 4% oxygen
tension, import of MNRR1 in the mitochondria is blocked with accumulation of the protein in the
nucleus at 8 hours (58). It is important to note that MNRR1 remains in the mitochondria during
this time-point and a hypothesis will presented in the results section as to why.

Figure 9. MNRR1/CHCHD2, CHCHD10, and Mix17. Alignment of human MNRR1/CHCHD2 and
CHCHD10 (D10) and yeast Mix17 protein sequences. Black boxes indicate conserved residues. Human
sequence annotation is as follows: Blue box indicates the CHCH domain. Solid black lines indicate the twin
CX9C motif. Dashed lines indicate the cysteine pairs that form structural disulfide bonds. The arrow
indicates the Y99 residue discussed elsewhere. This figure was obtained from Gladyck et. al., 2021 (99)
with the permission of the publisher (MDPI).

In the mitochondria, MNRR1 has been shown to interact with COX and regulate its activity
(113, 114). MNRR1 knockdown in cells affected multiple mitochondrial processes including a
~50% reduction of oxygen consumption rate, an increase in reactive oxygen species (ROS), a
reduction in mitochondrial membrane potential, slower growth (114), increased sensitivity to
apoptosis (61), and fragmented mitochondria, which increasingly form during oxidative stress
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(148-150). A large-scale protein–protein interaction study showed that MNRR1 interacts with two
COX subunits on the IMS-facing side of the IM (COX VIc and COX VIa1), as well as cytochrome
c, further suggesting that MNRR1 is a regulator of COX activity (151). However, further work is
needed as the interaction study, which was carried out with total cell lysate, also identified an
interaction with wholly matrix-localized COX subunits yet MNRR1 has not been detected in the
matrix (58). These identifications may not be physiological, as the matrix subunits would not
interact with MNRR1 in the IMS.
The interaction between MNRR1 and COX is promoted when MNRR1 is phosphorylated
at tyrosine residue 99 (Figure 9, arrow) by Abl2/Arg kinase (113). In order for this site-specific
phosphorylation to take place, CHCHD10 must be present. It has been shown that MNRR1 and
CHCHD10 are able to form homo- and hetero-dimers, potentially through the GXXXGXXXG motif
located near the center of the protein sequence in a conserved structural helix (152-154). The
glycine residues are of critical importance in protein-protein interaction, as illustrated through
residue mutational studies (155). Glycine has the smallest sidechain of the amino acids, and
therefore it is likely that these residues provide a flat interaction surface, allowing proteins to
interact closely with one another at this site (154). When Y99 is mutated to glutamate to mimic
phosphorylation, an increase in oxygen consumption is detected compared to WT. MNRR1 has
been shown to have another phosphorylation site, in the retained (non-cleaved due to IMS
localization) putative mitochondrial targeting sequence of the protein.
In the nucleus, MNRR1 acts as a transcriptional activator by binding to RBPJk at the highly
conserved oxygen responsive element (ORE) in the COX4I2 promoter, stimulating the expression
of the COX IV-2 subunit isoform, which is highly expressed in the lung, trachea, and carotid body
(73, 114, 147, 156, 157). Expression of COX IV-2 is maximal at 4% oxygen tension (73, 114, 147,
156). When COX IV-2 is present in the complex isolated from lung, COX activity was twofold
higher than the activity of COX isolated from liver with only COX IV-1 present (158). Genes that
harbor the ORE include mitochondrial proteases, ETC complex components (including subunits),
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and molecular chaperones, all of which are critical in maintaining mitochondrial homeostasis (99,
147). Based on this information, MNRR1 regulates COX activity and mitochondrial function with
a bi-organellar approach: both through physical interaction with the complex in the mitochondria
and through stress-induced transcription in the nucleus.
1.5.1 MNRR1 and Disease
Presently, alterations of MNRR1 have been associated with a handful of diseases,
including Parkinson’s disease (123), Huntington’s disease (124), lissencephaly (a neuronal
migration disorder) (125), Charcot-Marie Tooth disease (159), EGFR-positive non-small cell lung
cancer (128), hepatitis B or C virus-associated hepatocellular carcinoma (129), breast cancer
(126, 127) and very recently MELAS (58) (Table 2, Figure 10); Interestingly, CHCHD10 has also
been associated with several neurodegenerative diseases (130, 131, 134, 135, 160, 161).
MNRR1 has been shown to regulate cell migration (162), suggesting that it could be
important for metastasis in cancer and affecting migration in lissencephaly. Serine residue 41 has
been shown to be phosphorylated in breast cancer and levels of MNRR1 are also increased with
tumor grade, seemingly aiding the aggressiveness of breast cancer cells (126, 127).
A family with Charcot-Marie-Tooth disease type 1A has a Q112H mutation in MNRR1.
This mutation results in defective respiration and an exaggerated phenotype. We have shown
that the Q112H mutation in MNRR1 hinders its ability to interact with Abl2 kinase, resulting in
defective tyrosine phosphorylation and therefore defective mitochondria (113). Many of the
disease associated alterations of MNRR1 are mostly correlated with a change in protein levels,
suggesting that the MNRR1 mediated mitochondria-nuclear crosstalk could be dysfunctional in
these diseases. However, in most cases, the mechanistic involvement of MNRR1 in the disease
is unknown.
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Figure 10. The cellular functions and disease associations of MNRR1. Cellular functions are colored
in orange, neuro-type disease are colored in dark green, and cancers are colored in light green.

1.6 Parkinson’s Disease
Parkinson’s Disease (PD) is a complex, multifactorial neurodegenerative disorder that
affects more than 10 million people world-wide, according to the Parkinson’s Foundation, making
it the second most common neurodegenerative disorder. PD patients generally present with
movement symptoms that include resting tremor, rigidity, bradykinesia, and postural instability
(163). Patients also have non-motor symptoms as well, including depression, cognitive
impairment, autonomic nervous system dysfunction, sleep disturbance, pain, and gastrointestinal
issues, all of which are likely due to widespread degeneration within the nervous system (164,
165). PD can either be sporadic (majority of PD cases) or familial (autosomal dominant).
On a molecular level, PD is caused by death of dopaminergic (DA) neurons in the
substantia nigra pars compacta (SNpc) of the midbrain, which controls movement, and the
presence of alpha-synuclein aggregates, called Lewy Bodies, in the brain tissue due to a
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dysfunctional proteasomal pathway (166, 167). Excessive production in ROS, alterations to
catecholamine metabolism, decreased inflammatory response markers, dysregulation metal
cation homeostasis, overactive mtUPR, and impaired mitochondrial fission and fusion, and
dysfunctional

autophagy/mitophagy

have

also

been

associated

with

PD

(168-171).

Unsurprisingly, mitochondrial dysfunction has been shown in both early-onset familial and lateonset sporadic forms of PD (38, 164, 172). This is likely due to neuronal physiology, as these cell
types require an increased number of mitochondria due to high energy demands, which make
them sensitive to oxidative stress (173). Only a handful of genes have been identified as causing
pathogenicity within the etiology of the heritable form of the disease (and sometimes the sporadic
form) when they are altered (Table 3).
Table 3. Known genetic mutations in Parkinson’s Disease and effects on the mitochondria (172).
Gene Name/Protein

Healthy Gene Function

•
SNCA/alpha-Synuclein

•

•
•
LRRK2/Leucine rich repeat kinase 2
•
•

•
VPS35/Vacuolar protein sortingassociated protein 35

•
•
•

PRKN/E3 ubiquitin-protein ligase
parkin
•

PINK1/Serine-threonine protein
kinase pink1

•
•
•
•

Gene Dysfunction
• Forms aggregates called
May modulate synaptic
Lewy bodies (179)
transmissions (174)
• Induce mitochondrial
Can localize to the mitochondria
fragmentation and increase
(and MAM) and affect their
ROS (180, 181)
function (175-178)
• Lewy bodies
• Most common cause of AD
PD
• Mutations lead to increased
kinase activity
Serine/threonine kinase
• Affects mitochondrial fission
Neuronal plasticity (182)
and fusion (185)
Autophagy (183)
• Causes protein leak and
Neuronal vesicle trafficking (184) uncoupled respiration (186)
• Impairs mitophagy (187)
• Affects mitochondrial fission
and fusion (188)
Mediates retrograde delivery of
cargo from endosomes to Golgi
• Impairs complex I assembly
(189)
and activity (192)
Recycles endosomal cargo to
• Impairs mitochondrial fission
the cell surface
and fusion
Regulates mitochondrial fission
and fusion (190, 191)
• Most frequent cause of AR
E3 ubiquitin ligase involved in
PD (194)
proteasomal degradation and
cell signaling by targeting
• Dysfunctional mitophagy and
mitochondrial proteins (193)
biogenesis pathway (195)
Mitochondrial biogenesis and
• Loss of mitochondrial mass
mitophagy (38)
and respiration (196)
Serine/threonine kinase
• Reduced mitophagy (43)
Key regulator of mitophagy
• Mitochondrial calcium
overload (199)
Enhances fission in damaged
mitochondria (197)
• Reduction of complexes I
and III (200)
Mitochondrial biogenesis (198)

Type of PD

Autosomal Dominant

Sporadic

Autosomal Dominant

Sporadic

Autosomal Dominant

Autosomal Recessive

Sporadic

Autosomal Recessive
Sporadic
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ATP13A2/Polyamine-transporting
ATPase 13A2

MNRR1/CHCHD2

• Maintenance of neurons (201)
• May be involved in cation
transport and homeostasis
(mechanism unknown) (201)

• COX regulation (113, 114)
• Inhibitor of apoptosis (61)
• Transcriptional activator (114,
147)
• Cell migration (162)
• Mitochondrial morphology (206)

• Mutations cause KuforRakeb syndrome (juvenileonset PD) (202)
• Cation dysregulation (202,
203)
• Reduction in ATP
production(203)
• Increase in fragmentation
(201, 203)
• Increase in ROS (203)
• Impaired glycolysis(204)
• Defective lysosomal function
and mitophagy (172, 205)
• Decreased oxygen
consumption
• Increased ROS, DA neuron
degeneration, and shortened
lifespan (Drosophila) (207)

Autosomal Recessive

Sporadic

Autosomal Dominant

Sporadic

By the time patients are diagnosed with the disease, there is already substantial death of
DA neurons, and the degeneration has spread to other parts of the central nervous system (165).
There is no cure for PD but there are treatments such as dopamine replacement to manage
symptoms. This progressive disorder has a high socioeconomic burden to patients, as
therapeutics are quite costly (especially for the uninsured), not to mention the on-going care
required as those affected by the disease become less independent. Therefore, research into the
mechanism of the disease and the expansion of therapeutic targets to halt or slow the progression
of the disease is of incredible importance for patient care.
1.6.1 Parkinson’s Disease associated mutations in MNRR1
Genome-wide association studies have identified rare mutations in MNRR1 that are
associated with Parkinson’s Disease and other neurodegenerative disorders (Figure 10). The
mutations associated with neurodegeneration are interesting, as they span across the protein
sequence (Figure 11) and differ based on ancestral ethnicity. Meaning, MNRR1 mutations
associated with PD in Chinese and Japanese patients are not the same in Western
European/Caucasian patients (Table 4). All individuals who possess PD-associated variants are
heterozygous for the mutation, apart from one variant, A71P, which caused mitochondrial
dysfunction in patient fibroblasts (208). It is also worth mentioning that not all ethnic populations

22

(or cohorts) studied to date contain rare MNNR1 variants (209-215), suggesting that PDassociated mutations in MNRR1 may exacerbate an already complicated and heterogenic
disease.
The first rare MNRR1 PD-associated mutations were identified in a genome wide-linkage
study in a Japanese family with autosomal dominant PD as well as the Comprehensive Genetic
Study on Parkinson’s Disease and Related Disorders databank (123). Patients who were selected
for the study met the neurological exam criteria to submit DNA samples to the databank and had
no known PD-associated mutations. The novel variants T61I and R145Q were detected in 3 out
of the 340 Japanese families with autosomal dominant PD, while not detected in the control
population (n=559) or the sporadic PD population (n=517). The T61I mutation was also found in
a Chinese pedigree study in autosomal dominant PD patients (216). The T61I mutation will be
discussed further as it is of interest to this research.
Table 4. Rare mutations in MNRR1 that are associated with Parkinson’s Disease.
Mutation

Genotype

Pro2Leu

+/-

Arg8His
Ala32Thr
Pro34Leu
Ala49Val

+/+/+/+/-

Thr61Ile

+/-

Ala71Pro
Ala79Ser
Ile80Val
Gln126X
Arg145Gln

Associated Disease

Ethnicity

Reference

Japanese/Chinese
Chinese

(123, 216-219)

-/+/+/-

Sporadic
Early-onset
*Risk factor*
Sporadic
PD
PD
PD
Late-onset autosomal dominant
Autosomal dominant
Early onset PD with TOPIMT mutation
Sporadic
PD

Japanese
Western European
Western European
Caucasian
Japanese
Chinese
Caucasian
Chinese
Western European

+/+/-

Early-onset
Late-onset autosomal dominant

German
Japanese

(220)
(221)
(221)
(222)
(216, 223)
(208)
(224)
(221)
(225)
(123, 226)
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Figure 11. Alignment of MNRR1 (hCHCHD2) with neurodegenerative disorder mutations. This
alignment includes human CHCHD10 (isoform of MNRR1, hCHCHD10), and MNRR1 orthologs in C.
elegans (Har-1) and D. melanogaster (CG5010). Mutations are denoted with boxes with degree of
conservation: red (identical), purple (conserved), dashes (semi-conserved), and blue (not conserved). This
article was obtained from Kee et. al., 2021 (173) with the permission of the publisher (Frontiers).

Since the initial studies in patient populations were done to screen for rare PD-associated
variants, some functional studies have been done for some of the mutants, but the most
information to date is regarding the T61I variant. The first studies were performed in D.
melanogaster, which has ortholog of MNRR1 called CG5010. Flies over-expressing various
MNRR1 PD-associated mutations, including T61I, displayed decreased climbing ability over time,
which could be exacerbated by exposure to rotenone (complex I inhibitor) (207). The transgenic
flies also had a reduced lifespan, number of DA neurons, and mitochondrial dysfunction. Knockout
of CG5010 in flies results in an increase in ROS, disruption of mitochondrial structure, inhibition
of OXPHOS, resulting in the loss of DA neurons and motor dysfunction with aging (227). The
introduction of human WT MNRR1 was able to rescue the PD-associated phenotype while the
introduction of human T61I MNRR1 did not.

24

In HEK 293 cells, overexpression of the T61I mutation results in a greater binding affinity
for endogenous CHCHD10 and endogenous MNRR1 interaction (152, 228). Interestingly, the
T61I mutation occurs just outside of a GXXXGXXXG motif (Figure 11). It is important to note that
the presence of increased CHCHD10 in the pulldown performed could be due to the protein
binding to the endogenous WT MNRR1 in the lysate, and not necessarily due to interaction with
the overexpressed mutant. This would suggest an alteration in MNRR1 function in the
mitochondria, including COX regulation, as we have shown the interaction of CHCHD10 and
MNRR1 is necessary for finetuning COX activity (113).
1.7 Project Summary
MNRR1 has been shown to play a role in numerous pathways within cellular physiology
(Figure 10). Our lab is interested in studying the mitochondrial- and nuclear-specific functions of
the protein. The long-term goal of this project is to better understand the mechanisms by which
MNRR1 and its post-translational profile help to regulate mitochondrial respiration, apoptosis, and
nuclear transcriptional activation in basal and Parkinson’s disease backgrounds. A more complete
understanding of the impact of MNRR1 function in the mitochondria and nucleus is critical, as a
clearer functional picture may describe underlying functional mechanisms linked to disease and
cellular dysfunction, as well as provide a novel therapy target for diseases with a mitochondrial
dysfunction component.
One limitation to understanding the mitochondrion’s role in disease, stress signaling, and
metabolic pathways is the lack of functional characterization of much of the organelle’s proteome
as well as regulatory post-translational modifications. Therefore, the first aim of is project is to
understand how MNRR1 is turned over in the mitochondria during cellular stress. The second aim
is to determine where MNRR1 is binding on COX, how cytochrome c function is affected when
interacting with COX, and how phosphorylation of MNRR1 may be a regulatory switch between
cellular life and death. Finally, rare mutations in MNRR1 associated with Parkinson’s disease are
becoming a popular niche for research among the small group of researchers that study this
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protein. It an interesting topic, as patients in the flagship study had no known PD-associated
variants but had autosomal dominant PD in at least two generations of the family. The third aim
of this project is to add information to the emerging functional annotation of the PD-associated
T61I mutation of MNRR1.
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CHAPTER II: RESULTS
My thesis project would not have been possible without my many collaborators.
Collaborator experiments have been included in my thesis because they help to paint the
mechanistic picture of MNRR1. The experimental contributions are as follows: multiple
experiments in sections 2.1 and 2.3 were performed in part by Dr. Siddhesh Aras (Wayne State
University, Detroit, MI) as a collaborative effort to determine the mechanism of the stress
response activities of MNRR1. The spectral shift assay in section 2.2 was done by Dr. Sachiko
Yanagisawa (Hyogo University, Kakogawa, Japan) with materials prepared by me. The
ruthenium-labeled cytochrome c assay in section 2.2 was performed by Marti Scharlau in the
laboratory of Dr. Francis Millett (University of Arkansas, Fayetteville, AR, USA) with materials
prepared by me. All contributions are denoted in figure legends and specifically acknowledged in
Chapter IV: Materials and Methods.
2.1 MNRR1 turnover and implications in a mitochondrial stress response
2.1.1 MNRR1 is not targeted by the ubiquitin-proteasomal system during moderate hypoxia
Previous studies in our lab show that MNRR1 is upregulated at 4% oxygen tension and
that the nuclear levels of the protein increase, while mitochondrial levels decrease (114, 147).
Others have used a quantitative proteomics approach which showed that MNRR1 is one of the
most rapidly turned over proteins in the cell (229). During 20% oxygen tension, total cellular
MNRR1 is degraded after 3 hours of stalled translation; however, at 4% oxygen, MNRR1 is
completely lost by 3 hours suggesting that MNRR1 is more rapidly turned over at 4% oxygen
tension (58). Our lab has also found that MNRR1 was more rapidly turned over in the
mitochondria, where turnover happens within an hour of stalled translation. The nuclear fraction
of MNRR1 is mostly turned over by hour two, suggesting that during moderate hypoxic stress, the
levels of MNRR1 are more stable in the nucleus compared to the mitochondria (58).
It has been shown that during cellular stress the mitochondrial proteome can be
ubiquitinated and degraded by the cytosolic proteasomal system to regulate function and stress
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response (230, 231). Larance et. al. (229) showed that MNRR1 was not a target for the
proteasomal system because turnover of MNRR1 still occurred with proteasome inhibition using
MG132. We confirmed this finding by looking at the ubiquitination profile of MNRR1 in cells
maintained at 20% and 4% oxygen tension using immunoprecipitation. The resulting pulldown
revealed that there was no difference in the ubiquitination profile of MNRR1 between basal and
stress conditions, ruling out the ubiquitin proteasomal system as responsible for mitochondrial
MNRR1 turnover (Figure 12).
4%
20%
Oxygen Oxygen

Figure 12. MNRR1 is not targeted by the ubiquitin-proteasomal system. HEK 293 cells were cotransfected with MNRR1-FLAG and UB-HA expression plasmids; 24 hours post-transfection, one plate was
moved to 4% oxygen for 12 hours. Cells were then harvested and lysed. The lysate was immunoprecipitated
with FLAG beads and probed with HA to look at the ubiquitination profile of MNRR1 in 20% vs 4% oxygen.
Published in PNAS (58).

2.1.2 YME1L1 is a candidate protease for MNRR1 turnover in the mitochondria
Identifying the protease(s) responsible for turnover of MNRR1 in the mitochondria during
moderate hypoxic stress became an important mechanistic question. We knew the ubiquitin
proteasomal system was not responsible, so it must be a protease localized within the
mitochondria during basal or stress conditions. We chose to focus on two AAA-proteases:
YME1L1 and LONP1. These proteases play important roles in mitochondrial protein quality
control systems (232, 233). Although both proteases reside within the mitochondria, it has been
predicted that LONP1 resides solely in the matrix (233) and that YME1L1 is bound to the IMS
side of the IMM (234). MNRR1 is a soluble IMS protein and, although it retains its N-terminal MTS,
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we have yet to observe its localization to the matrix. To ensure that our localization model was
correct, we checked the protein compartmentalization through mitochondrial fractionation.
Indeed, MNRR1 and YME1L1 were found to localize to the IMS, while LONP1 localizes to the
matrix (Figure 13A).
We have shown that MNRR1 levels increase at 4% oxygen tension in cells and that during
this moderate stress, MNRR1 predominately localizes to the nucleus where it acts as a
transcriptional activator at the ORE. We were interested to know if YME1L1 protein levels
increase at this same oxygen tension, where we see a decrease in mitochondrial MNRR1. Cells
were maintained at 20% and 4% oxygen tension and, it was determined that YME1L1 protein
levels increase at 4% oxygen (Figure 13B, top). Given our model of MNRR1 transcriptional
activation in the nucleus, our hypothesis was that if YME1L1 gene contains an ORE, the
expression could be regulated by MNRR1 during stress. As expected, a promoter scan resulted
in the identification of the COX4i2 ORE in the YME1L1 promoter (Figure 13B, bottom), suggesting
that MNRR1 is a transcriptional regulator of its target protease.
To test if YME1L1 was able to directly degrade MNRR1, an in vitro protease assay was
performed with purified YME1L1 (catalytic domain), MNRR1, and bovine liver COX. In the reaction
containing YME1L1, it was observed that the levels of MNRR1 decreased slightly compared to
the no-protease control (Figure 13C). The MNRR1 degradation by YME1L1 was specific, in that
COXIV levels did not differ between the presence or absence of the protease (Figure 13C). It
should be noted that this experiment needs to be repeated using a known YME1L1 target
substrate as a positive control to ensure that the catalytic domain of the enzyme is functionally
active.
To determine if the turnover of MNRR1 by YME1L1 was true in cell culture models,
YME1L1 was knocked down in HEK 293 cells using siRNA. The knock down of YME1L1 resulted
in an increase in MNRR1 protein levels (Figure 13D, left), suggesting that the protein is stabilized
at the depletion of YME1L1. In YME1L1-/- MEFs, we observed the same result (Figure 13D, right).
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These experiments collectively suport that YME1L1 is a protease responsible for targeting
MNRR1
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Figure 13. MNRR1 is targeted for degradation by IMS protease YME1L1. A. IMS and matrix
compartments were isolated from HEK 293 mitochondria#. Compartment lysates were assessed for the
presence of the of the indicated proteins. B. Top, total YME1L1 was detected in HEK 293 cells that were
incubated at 20% or 4% oxygen tension for 24 hours. Tubulin served as a loading control. Bottom, YME1L1
promoter ORE aligned to classical COX4I2 ORE. C. In vitro protease degradation assay using purified
YME1L1, MNRR1, and COX. D. MNRR1 levels were analyzed in YME1L1 knockdown HEK 293 cells using
siRNA (left) or YME1L1 knockout MEFs# (YME1-/-) (right). GAPDH served as a loading control. #This
experiment was done by Dr. Siddhesh Aras, Wayne State University, Detroit, MI and are published in PNAS
(58).

2.1.3 MNRR1 is involved in the mitochondrial unfolded protein response
YME1L1 has been shown to be a key player in the mitochondrial unfolded protein
response (mtUPR) (47). When protein misfolding occurs in the mitochondria, a stress response,
similar to that of the endoplasmic reticulum UPR (erUPR) (235) is set in motion (45, 46). Stress
signaling from mitochondria to the nucleus kicks off transcriptional activation of proteins required
to restore protein homeostasis in the organelle.
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We have shown that under moderate hypoxic stress MNRR1 levels increase in the
nucleus and decrease in the mitochondria (114) and that MNRR1 may serve as a transcriptional
activator for YME1L1, we were interested in determining if MNRR1 plays a role in the mtUPR.
Therefore, we looked at protein levels of key mtUPR regulators in MNRR1-/- cells (Figure 14A).
Depletion of YME1L1, LONP1, NRF-1, and Hsp60 protein levels were observed in the MNRR1-/cells as compared to the WT cells, suggesting that MNRR1 may transcriptionally regulate other
mtUPR proteins besides YME1L1.
Our lab has shown that mtUPR induction at the protein level of Hsp60 did not occur in
MNRR1-/- cells treated with doxycycline (an inducer of mtUPR) (58). To confirm that MNRR1 was
involved in the transcriptional regulation of mtUPR response, our dual luciferase COX4I2 ORE
and Mutant ORE (no RBPJk binding sequence) was transfected into cells which were treated with
doxycycline for 48 hours (Figure 14B). The WT ORE reporter a statistically significant increase in
activity compared to its control, whereas the mutant ORE response was blunted with no significant
change compared to control. The increase in seen in WT ORE transcriptional activity was also
significant from that seen in the mutant. This data is supported by the observation of similar effects
with our MNRR1 ORE luciferase reporter and other mtUPR inducers shown elsewhere (58).
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Figure 14. MNRR1 is involved in mtUPR signaling in the nucleus. A. Protein levels of key mtUPR
markers in MNRR1 knockout HEK 293 (R1-/-) cells compared with control cells (WT). GAPDH and actin
served as loading controls. B. Dual luciferase assay in HEK 293 cells expressing the WT or Mutant COX4I2luciferase reporter treated with mtUPR inducer doxycycline (50 μg/mL) for 48 h. Data are presented relative
to cells treated with vehicle. ** p<0.01.

2.1.4. The mechanism of MNRR1 in mtUPR
Taken together, these data support that MNRR1 plays an active role in mtUPR signaling
via its nuclear function. The proposed mechanism based on the above data is that during
proteotoxic stress due to misfolded proteins in the mitochondria, MNRR1 rapidly accumulates in
the nucleus due to the blockage of import (Figure 15). At the same time, the mitochondrial pool
of MNRR1 that is interacting with COX is rapidly turned over by YME1L1 to attenuate
mitochondrial metabolism. In the nucleus, ORE containing genes involved in the mtUPR are
actively expressed and allow for the rescue of proteotoxicity in the mitochondria, restoring
organelle homeostasis.
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Figure 15. The role of MNRR1 in mtUPR . Left, under non-stress conditions most of the cellular MNRR1
is bound to COX in the mitochondrial IMS, with a fraction localized to the nucleus. Right, mitochondrial
stress due to proteotoxicity initiates the mtUPR. MNRR1 is rapidly turned over by YME1L1, while blocked
IMS import results in MNRR1 accumulating in the nucleus. The increase in MNRR1 levels results in the
displacement of ORE repressors and transcriptional activation of mtUPR genes occurs in attempt to restore
mitochondrial homeostasis.

2.2 MNRR1 modulates COX activity through direct interaction with the complex
2.2.1 Purification of HIS-MNRR1 from Escherichia coli
Our lab has previously shown that MNRR1 regulates COX activity and that
phosphorylation of tyrosine residue 99 (Y99) plays an important role in fine-tuning oxygen
consumption (113, 114). One unanswered question was if MNRR1 directly regulates COX activity
through interaction or if this was an indirect effect. To answer this question, large quantities of
MNRR1 would need to be purified from bacteria.
Given the unique properties of MNRR1 (numerous redox sensitive cysteines, disulfide
bonded folding, and highly disordered regions within the protein), every step of the purification
process needed to be optimized. The original protocol used in the lab for 6xHIS-tagged MNRR1
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(HIS-MNRR1) expression in BL21(DE3) E. coli did not result in a high yield (Figure 16A) or a
clean preparation of purified target protein (Figure 16B). Thus, the protein expressed and purified
using this protocol was not suitable for in vitro assays, where protein purity plays an important
role in the accuracy of measurements.
Therefore, a highly specialized strain of E. coli, SHuffle® T7 Express lysY (NEB), was
used to ensure proper protein folding in the bacterial cytoplasm. DsbC is a soluble, enzymatic
chaperone that catalyzes the formation of disulfide bonds in the oxidizing environment of the
periplasm of bacterial cells (236, 237). This strain of E. coli expresses DsbC in the cytoplasm.
The co-expression of DsbC has been shown to increase expression of the target protein and to
help increase purity of preparations (238-240). This strain also contains mutant lysozyme,
allowing competent bacteria to survive toxic protein expression, which is visible as the highly
degraded product seen in BL21(DE3) (Figure 16B). The implementation of the SHuffle® T7
Express lysY resulted in higher protein expression (Figure 16C) as well as a highly pure protein
purification yield (Figure 16D).
A secondary issue was also addressed in post-purification, after protein concentration.
Recombinant MNRR1 left in the high-salt purification buffer would result in the protein irreversibly
precipitating out of solution. To address this issue, different storage buffer formuations were used,
including high glycerol content and low salt concentrations. Glycerol was used to prevent the
protein aliquots from freezing; however, high glycerol content can affect protein-protein
interactions. Taking the downstream applications for which the recombinant protein would be
used in to account, it was determined that a low salt, glycerol free buffer allowed the protein to
stay in solution during storage. To prevent freeze-thaw of the protein, small volume aliquots were
made and stored at -80˚C. For more information on other modifications made during the
purification process please see Materials and Methods Section 4.5.
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Figure 16. Purification optimization for HIS-MNRR1. A. Expression test of transformed BL21(DE3) E.coli
transformed with 6xHIS-MNRR1 expression plasmid. Whole bacterial lysate is shown on Coomassie blue
stained gel. B. Pooled elution fractions from nickel column purification showing massive degradation and
co-purifiers when 6xHIS-MNRR1 is purified from BL21(DE3) E. coli. C. Expression test of SHuffle® T7
Express lysY E. coli. D. Comparison of end product between 6xHIS-MNRR1 expressed in BL21(DE3) (Old
Protocol) and SHuffle® T7 Express lysY (New Protocol). -IPTG denotes the uninduced control culture,
+IPTG denotes the induced culture, * indicates the intact 6xHIS-MNRR1 protein.

2.2.2 MNRR1 changes COX activity through direct interaction near the cytc binding pocket
To test if the addition of MNRR1 to an in vitro system affects COX activity, oxygen
consumption was measured using a Clark-type oxygen sensing electrode. The addition of
unphosphorylated (WT) MNRR1 resulted in an ~20% increase in COX activity (Figure 17A). As
expected, the phosphomimetic (Y99E) MNRR1 maximally increased COX activity, superior to that
of WT. This in vitro data supports our cell culture model and shows that, in both cases, Y99
phosphorylation of MNRR1 is a critical PTM in fine-tuning the activity of the tightly regulated
complex IV.
Another important question in this study was where MNRR1 binds to COX to regulate the
activity of the complex. A high throughput interaction study performed using affinity capture-mass
spectrometry (AP-MS) revealed a handful of COX subunits as potential MNRR1 interactors: COX
Va, COX Vb, COX VIa, and COX VIc (151). However, the COX V subunit isoforms localize to the
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mitochondrial matrix side of the membrane (Figure 17B), suggesting that their capture is an
artifact of using whole cell lysate in the experiment. COX VIa is almost exclusively inserted into
the inner mitochondrial membrane, although ~20 amino acid residues extend into the IMS, as is
true with of the COX VIc subunit (Figure 17B).
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Figure 17. MNRR1 regulates COX activity through direct interaction near the cytc binding pocket.
A. In vitro COX activity in the absence and presence of WT MNRR1 and Y99E MNRR1. *p<0.05, **p<0.01,
***p<0.001 B. COX structure (67). COXVa (pink), COXVb (purple), COXVIa (red), and COXVIc (light green).
Hemes (dark blue) and copper (orange circles). C. Oxidized spectrum of bovine liver COX in the absence
and presence of recombinant WT MNRR1.# D. Cross-linking-MS peptide identification of COX6c and
MNRR1. E. COX6c interacts with the holoenzyme, circled in purple. #This experiment was performed by
Dr. Sachiko Yanagisawa (Hyogo University, Kakogawa, Japan) with materials prepared by me. Figures 1B
and modified 1E were obtained from Kadenbach and Hüttemann, 2015 (67) with permission from the
publisher (Elsevier).
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To detect the physical interaction of MNRR1 and COX, the UV-VIS absorbance spectrum
of COX was measured in the absence and presence of WT MNRR1. A shift in the absorbance
spectrum of COX in the presence of WT MNRR1 indicates a physical interaction and a potential
location of the interaction between the protein and the COX complex. The measurements showed
a slight shift in the absorbance spectrum of COX in the presence of WT MNRR1, from 412 nm to
436 nm (Figure 17C, green line). The shift in the spectra between these wavelengths suggests
that a structural change is occurring in the heme vicinity of COX because the heme absorption
spectrum is observed from 410-460 nm (241). The hemes are located in the holoenzyme of the
complex in COX subunit I and are involved in electron transfer.
To determine where MNRR1 may be binding and inducing structural changes in COX, in
vitro crosslinking was performed followed by mass spectrometry. The results showed only one
band containing peptide from both WT MNRR1 and a COX subunit, which was identified as COX
VIc (Figure 17D). COX VIc binds to subunits I (location of the heme groups) and II on the outside
of the complex (Figure 17E). This subunit also protrudes into the IMS and is located near the cytc
binding pocket, suggesting that MNRR1 regulates the interaction between the electron shuttle
and COX.
2.2.3 Phosphorylated MNRR1 influences the binding between cytc and COX in vitro
Given the evidence that MNRR1 likely binds near the cytc binding pocket and induces
structural changes within the complex itself, we assessed cytc-COX interaction by measuring in
vitro electron transfer and binding affinity. Measurements were taken spectroscopically using a
ruthenium labeled derivative of cytc (Ru-cytc). Ruthenium is a rare transition metal that can act
as an electron donor through metal to ligand transfer. The ruthenium moiety is added to cytc at
residue C39 (mutated from lysine), which was shown to have similar kinetics as wildtype cytc
(242). With laser excitation, ruthenium transfers an electron to cytc, which is then subsequently
accepted by COX via the CuA site (Figure 18A) (243). In the assay, the rate constant of electron
transfer from Ru-cytc to the CuA site of bovine liver COX (ka) was unaffected by the presence of
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recombinant WT or Y99E MNRR1. However, in the presence of increasing ionic strength, a
difference in the rate constant for the formation of 1:1 cytc:COX complex (kf) is observed (Figure
18B). The kf is lower for COX control and in the presence of recombinant WT MNRR1 as
compared to when recombinant Y99E MNRR1 is present. Phosphorylation at Y99 appears to
stabilize the cytc:COX complex when exposed to increasing NaCl concentrations.
B
COX ka
COX kf

A

Y99E kf
WT kf

Figure 18. Phosphorylated MNRR1 affects the binding kinetics between COX and cytc. A. Electron
flow (blue arrows) from Ru-39-cytc to COX (243). B. Electron transfer measurements (brown square) (ka)
and cytc:COX binding in increasing amounts of NaCl in the absence (red circles) and presence of
recombinant MNRR1(kf) (WT, blue diamond and Y99E, green triangle). This experiment was performed by
Marti Scharlau in the laboratory of Dr. Francis Millett (University of Arkansas, Fayetteville, AR, USA) with
materials sent by me. Figure 18A was obtained from Scharlau et. al., 2019 (243) with permission for use
from the publisher (ACS Publications).

2.3 Unphosphorylated MNRR1 preferentially interacts with Bcl-xL
A previous study had suggested that MNRR1 plays a role in apoptosis in the mitochondria.
In that study, it was shown that MNRR1 knockout cells are sensitized to apoptosis because BclxL is unable to inhibit Bax activation and that MNRR1 interacts with Bcl-xL at the IMS facing side
of the OMM (61). Our hypothesis was that the unphosphorylated pool of MNRR1 in the
mitochondria mostly interacts with Bcl-xL, while the phosphorylated pool of MNRR1 is reserved
for COX regulation.
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To test this hypothesis, flag-tagged phosphomimetic (Y99E) or unphosphorylatable
(Y99F) MNRR1 was overexpressed in HEK 293 cells. Immunoprecipitation was performed with
FLAG beads and the presence Bcl-xL was assessed in the pulldown. An increase in Bcl-xL protein
was observed in the Y99F MNRR1 pulldown as compared to the Y99E MNRR1 pulldown (Figure
19A). This finding supports the hypothesis of unphosphorylated MNRR1 playing a role in the antiapoptotic function of the protein.
The proposed complete model for MNRR1 function in the mitochondria is presented in
Figure 19B. In this model, MNRR1 interacts with COX, where Y99 phosphorylation plays a role in
the fine-tuning of COX activity through cytc interaction. Due to the location of COX in the IMM,
YME1L1, another membrane bound protein, can turn over the phosphorylated pool of MNRR1 as
needed for adaptation to stress. This allows for the unphosphorylated pool of MNRR1 to remain
bound to Bcl-xL on the IMS side of the OMM, giving the cell time to return to homeostasis after
stress insult, by inhibiting apoptosis.
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Figure 19. Unphosphorylated MNRR1 preferentially interacts with Bcl-xL. A#. HEK 293 cells were
transfected with FLAG tagged phosphomimetic (Y99E) or unphosphorylated (Y99F) MNRR1. MNRR1 was
immunoprecipitated using anti-FLAG antibody and the precipitate was probed for Bcl-xL and FLAG. B. The
working model of MNRR1 function in the mitochondria. Phosphorylated MNRR1 (purple oval with grey dot)
preferentially interacts with COX to attenuate COX activity. Due to the proximity COX-bound MNRR1 to the
IMM, YME1L1 turns over the phosphorylated MNRR1 pool during stress, leaving the unphosphorylated
MNRR1 to inhibit apoptosis through Bcl-xL interaction. #This experiment was done by Dr. Siddhesh Aras,
Wayne State University, Detroit, MI and included to complete the model of MNRR1 in the mitochondria.

2.4 MNRR1 in Parkinson’s Disease
2.4.1 MNRR1 cannot rescue OXPHOS defects seen with MPP+ treatment
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It has been suggested that PD-associated mutations in MNRR1 may lead to mitochondrial
dysfunction and oxidative stress (207). To test this hypothesis in vitro, purified proteins were used
to measure COX activity. The T61I PD-associated mutant was included in this study because it
is the most studied of the rare mutants, but more information is needed to fully understand the
pathogenic alterations to the protein’s function. Oxygen consumption was measured using a
Clark-type oxygen sensing electrode. The Y99E control produced an ~20% increase in COX
activity (Figure 20A). The T61I mutant did not produce a change in COX activity upon addition to
the electrode chamber, indicating that in the in vitro system this PD-associated mutant does not
alter COX activity. However, PD patients harboring the T61I mutant are heterozygous at the
CHCHD2 locus, meaning they have one WT allele present, suggesting the mutant allele has a
dominant-negative effect. The in vitro finding may not necessarily reflect the physiology of the
heterozygous phenotype because only one type of MNRR1 was added to the chamber for COX
activity measurement, which is why it was important to test the mutant in a WT cell culture model.
To find an appropriate system to induce a PD phenotype in WT SY5Y cells, MPP+ was
used. MPP+ was discovered to induce rapid PD phenotypes in drug users when the precursor
metabolite was found to be an ingredient in synthetic heroine (244, 245). MPP+ uses the
dopamine transporter to enter DA neurons, after which it enters the mitochondria and inhibits
complex I; it has thus become a common PD phenotype inducer in mammalian systems.
To test whether the T61I mutant was defective for oxygen consumption rate (OCR) in WT
SY5Y cells, intact cellular respiration was measured in both vehicle and MPP+ transfected cells.
Both WT and T61I cells showed a significant decrease in OCR with MPP+ treatment compared
to the vehicle control (Figure 20D).
Since MNRR1 is a biorganellar protein, it was important to determine if the T61I mutant's
effect was mediated in the nucleus or in the mitochondria. To do so, the mitochondrial import
deficient mutant (C-S) of MNRR1, which stimulates transcriptional activation at the ORE in the
nucleus, and our Y99E mutant, which stimulates respiration in the mitochondria were utilized. To
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answer this question WT SY5Y cells were transfected with WT, C-S, or Y99E MNRR1 and either
treated with vehicle or MPP+ before intact respiration was measured. Neither the overexpression
of C-S or Y99E MNRR1 could rescue the defects observed in OCR in the presence of MPP+
treatment, indicating that MNRR1’s nuclear activity or post-translational status cannot overcome
MPP+ inhibition (Figure 20B).
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Figure 20. T61I mutant is defective for oxygen consumption and MPP+ phenotype cannot be
rescued by MNRR1 overexpression. A. In vitro COX activity in the absence and presence of Y99E and
T61I MNRR1. **p<0.005, ***p<0.001 B. Relative oxygen consumption rate (OCR) of intact WT SY5Y cells
expressing WT, T61I, C-S, and Y99E MNRR1 pre-treated with 250 µM MPP+ of DMSO vehicle for 7 hours.
Measured in Seahorse bioanalyzer. MPP+ treatment is normalized to respective vehicle controls for
comparison. Flag expression is shown below (loaded by volume). *p<0.05, **p<0.005.

2.4.2. The expression of T61I in WT SH-SY5Y cells affects the nuclear function of MNRR1
MNRR1 has been shown to activate transcription of stress response genes in cells.
MNRR1-mediated transcription has not yet been studied in PD. To determine whether MNRR1
over-expression can alter transcription at the ORE, WT, C-S, T61I, and Y99E MNRR1 variants
were co-transfected into SH-SY5Y cells with our MNRR1 ORE reporter plasmid. Cells were
subsequently treated with DMSO vehicle or MPP+ for 24 hours and relative luminescence from
the reporter plasmid was read. The C-S mutant, which is defective for mitochondrial import but
can perform its nuclear function (114), behaved as expected by increasing transcripts despite the
presence of MPP+. Others in the lab have shown that Y99E MNRR1 is defective for transcriptional
activation using our reporter (data unpublished) and this was reproduced in the assay.
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The T61I mutant behaved in an interesting manor, where under basal conditions, an
increase in transcriptional activation was observed mirroring that which is observed with the C-S
MPP+ treated cells. However, with MPP+ treatment there is a decrease in the reporter activity in
the T61I cells. Taken together, the data suggests that the nuclear behavior of MNRR1 is affected
by the T61I mutation.
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Figure 21. T61I MNRR1 is defective for transcriptional activation at the MNRR1 ORE. Activity
measurements were taken in WT SH-SY5Y cells co-transfected with the MNRR1 ORE reporter, internal
control luciferase, and the indicated MNRR1 expression plasmid. Cells were then treated with DMSO
vehicle or 500 µM MPP+ for 24 hours. Relative luminescence was measured and normalized to the internal
control luciferase. Experiment must be repeated once more for statistics.

2.4.3. T61I mutant may cause an imbalance in compartment-specific mtUPRs
Due to the ORE transcriptional changes observed with the T61I mutant, protein levels
were investigated for CHCHD10 (transcriptional repression at the ORE) and mtUPR markers
(Hsp60 and YME1L1) in WT or T61I transfected WT SH-SY5Y cells treated with either vehicle or
500 µM MPP+ for 24 hours. In the T61I cells, we see an increase in CHCHD10 levels compared
to untreated and WT treated cells (Figure 22A). The reduction in reporter activity may be due to
the rise in CHCHD10 levels, as our lab has previously shown CHCHD10 to act as a transcriptional
repressor of the ORE (115). Confirmation experiments will need to be performed to determine if
CHCHD10 levels increase in the nucleus in the presence of T61I with MPP+ stress.
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When assessing the levels of endogenous and Flag-tagged transfected MNRR1, it was
observed that T61I (top band) and endogenous (WT) MNRR1 (bottom band) levels were lower in
vehicle treated cells compared to WT cells, with the most noticeable decrease observed with the
T61I protein (Figure 22B). Both endogenous and T61I MNRR1 increased with MPP+ treatment
(Figure 22B). This was unexpected, as we see repression of the MNRR1 ORE in the T61I cells
with MPP+ treatment, leading to a hypothesis that this type of stress may stabilize MNRR1 in
cells.
As previously discussed in Results Section 2.1, YME1L1 is a protease that targets MNRR1
in the mitochondria. While no change in YME1L1 protein levels was observed in WT expressing
cells, there were differences in the T61I cells (Figure 22C). In vehicle T61I cells, the levels of
YME1L1 are higher compared to WT controls. This finding could be an explanation for the
reduction in T61I and endogenous MNRR1 levels we see in the same cells. In the MPP+ treated
T61I cells, the levels of YME1L1 are depleted compared to the vehicle control, supporting the
hypothesis that T61I and endogenous MNRR1 proteins are stabilized with MPP+ treatment. The
levels of Hsp60 were also altered in the T61I expressing cells, but not WT expressing cells.
Compared to the vehicle control, the level of Hsp60 drastically increased in MPP+ treated T61I
cells (Figure 22D).
When the data is analyzed cumulatively, a soft hypothesis can be made, with the caveat
that many more experiments need to be performed to solidify a mechanism of T61I functional
alterations that contribute to PD. This data suggests that under basal conditions, T61I stimulates
MNRR1 nuclear activity (potentially through a stress response or mis-localization), where we see
an increase in YME1L1 protein levels. The localization of YME1L1 coupled with an increase in
protein level may result in a mtUPR response in the IMS, turning over the T61I mutant, while not
inducing the matrix mtUPR; this is reflected by uninduced Hsp60 levels in the T61I cells compared
to WT. When the T61I cells undergo oxidative stress due to MPP+ treatment, ORE activity is
inhibited in the nucleus due to the rise in CHCHD10 protein levels. T61I and endogenous MNRR1
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are stabilized during this stress due to a decrease in the levels of YME1L1 protein, which could
be indicative of a dysfunctional IMS mtUPR. Hsp60 levels increase in these conditions,
suggesting that the matrix mtUPR is activated by an unknown mechanism.
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Figure 22. T61I MNRR1 may cause an imbalance in compartment mtUPR activation. A. Western blot
showing protein levels in lysate from WT SH-SY5Y cells transfected with indicated MNRR1 expression
plasmid. Transfected cells were treated with DMSO vehicle (-) or 500 µM MPP+ (+) for 24 hours before
harvest. Gapdh was used as a loading control for soluble proteins and Complex II (SDH) was used as a
loading control for membrane protein.
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CHAPTER III: DISCUSSION
Mitochondrial-nuclear crosstalk is a crucial molecular mechanism that allows the
mitochondria to relay a message to the nucleus to maintain or restore cellular homeostasis (246,
247). Our lab has shown that MNRR1 is a multi-functional protein, performing specific duties in
the mitochondria and the nucleus dependent upon stress crosstalk. In the mitochondria, we have
previously shown that MNRR1 regulates COX activity, and that the regulatory activity can be finetuned through phosphorylation of residue Y99 (113, 114). We have also identified MNRR1 as a
transcriptional activator in the nucleus during inducible stress (58, 147). Others have shown that
MNRR1 plays an anti-apoptotic role in the mitochondria by demonstrating the inability of Bcl-xL
to prevent the release of cytc during cellular stress in MNRR1 knockout cells (61).
As mentioned above, during times of stress, such as moderate hypoxia, MNRR1 activates
transcription in the nucleus. Our lab showed that bi-organellar levels of MNRR1 switch upon
cellular stress so that MNRR1 accumulates in the nucleus due to inhibited mitochondrial import,
resulting in decreased mitochondrial MNRR1 protein levels. These results suggest that there is a
delicate balance required by the remaining mitochondrial MNRR1 to deal with stress attenuation
while inhibiting apoptosis, giving the cell time to repair itself through retrograde signaling.
The research presented here suggests that phosphorylation of residue Y99 is a key
regulator of this balance between life and death decisions. Under basal conditions, mitochondrial
MNRR1 binds to COX, whereby unphosphorylated MNRR1 can increase activity of the enzyme
complex and Y99 phosphorylation results in maximal activity (Figure 17A). Depending on the
energetic need of the cell, it is possible that MNRR1 is preferentially phosphorylated or
dephosphorylated, which acts as a mechanistic switch. During cellular stress, we observe the
rapid reduction of MNRR1 protein levels in the mitochondria (Figure 12B) and an accumulation of
MNRR1 in the nucleus for transcriptional activation to take place; however, some MNRR1 remains
in the mitochondria (58, 114). A hypothesis of this project was that unphosphorylated MNRR1
may preferentially interact with Bcl-xL, allowing it to remain in the mitochondria, inhibiting
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apoptosis and giving the nucleus time to facilitate a cellular rescue response to deleterious stimuli.
An immunoprecipitation assay showed that the unphosphorylated mutant of MNRR1 preferentially
interacts with Bcl-xL compared to the phosphomimetic MNRR1 (Figure 19A).
Further studies should be done to complement our localization microscopy shown
elsewhere (58). The data shows that MNRR1 remains in the mitochondria of cells incubated at
4% oxygen tension for 8 hours, accompanied by nuclear accumulation due to blocked IMS import.
To understand the full picture of the above proposed mechanism, microscopy should be done at
4% oxygen tension for longer time points, including 12 hours (where reporter activation was
observed), 24 hours (used in other experiments), etc. The time points will give an accurate
depiction of bi-organellar MNRR1 localization during acute and chronic stress and determine the
timeframes of the functions of MNRR1 in transcription, OXPHOS, and apoptosis. The addition of
functional studies at each time point would also add to the study, such as assessing ORE
transcriptional activation, COX activity, and apoptosis.
Another important question addressed in this project was regarding how MNRR1 was
being turned over in the mitochondria during stress. We have observed MNRR1 localizing to the
mitochondrial IMS via the Mia40 import machinery (114) and have yet to observe conditions in
which MNRR1 uses its retained MTS to enter the mitochondrial matrix. A classic pathway in
mitochondrial protein turnover is the ubiquitin-proteasomal pathway (53); however, the
ubiquitination profile of MNRR1 did not change between basal and stressed conditions (Figure
1C). The next logical step in identifying a candidate protease that targets MNRR1 as a substrate
was to test proteases with access to the IMS. YME1L1 is a membrane bound protease that
protrudes into the IMS (Figure 13A). YME1L1 levels also increase at 4% oxygen tension (Figure
13B) and contains an ORE in the promoter of its gene, which suggests that MNRR1 is a
transcriptional activator of the protease during stress. In both YME1L1 knockdown and knockout
cells, the reduction in the protease results in the stabilization of MNRR1 protein levels (Figure
13D-E).
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YME1L1 is a key regulator of proteotoxic stress in the mitochondria and participates in the
mtUPR (47, 232). The fact that MNRR1 is a transcriptional activator in conditions that cause
mitochondrial proteotoxic stress further implicates its role in crosstalk signaling. It was determined
that MNRR1 does indeed play a transcriptional activation role in the mtUPR via the upregulaton
of YME1L1 and HSP60 (a protein folding chaperone) (Figures 13B and 14B). Additionally,
MNRR1 deficient cells were unable to induce a mtUPR response as apparent by reduction in key
players in the pathway (Figures 14A-B).
The identification of YME1L1 as a protease that facilitates mitochondrial MNRR1 turnover
further supports the notion that unphosphorylated MNRR1 is left in the mitochondria to regulate
apoptosis. This hypothesis is based upon proximity of the protease to the OMM. As discussed
above, YME1L1 is an IMM bound protein with the catalytic domain protruding into the IMS.
Additionally, COX is a transmembrane complex with MNRR1 binding on the IMS-facing side. This
would place the pool of MNRR1 directing COX activity within reach of YME1L1 and thereby
attenuating COX activity through turnover during stress. The Bcl-xL bound pool of mitochondrial
MNRR1 would be out of reach of the protease, allowing for its antiapoptotic function to remain
intact (Figure 19B).
Another important question addressed in this study is regarding where MNRR1 is binding
on COX. Of the potential subunits identified by Floyd et. al (151) in their high throughput AP-MS
study, it seemed that the IMS protruding subunits COX VIa and COX VIc were the most likely
candidates due to the mitochondrial compartment localization of MNRR1. The use of tissuepurified COX and recombinant MNRR1 for irreversible chemical cross-linking seemed like the
most straightforward approach. However, it should be noted, that tissue-purified COX has
hundreds of co-purifying proteins (Hüttemann Lab, unpublished MS data); it is, after all, how our
lab was able to determine that MNRR1 interacts with the complex (114). Immunoblotting allowed
us to track MNRR1 binding in the crosslinking reaction to COX and unconventional mass spec
was performed from membrane bands. Despite low peptide count (likely due to the high sensitivity
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of the FLAG antibody used), peptides from MNRR1 and COX VIc were found in the same band,
suggesting interaction (Figure 17D).
The function of COX VIc is not well understood; however, mutations of the D.
melanogaster COX VIc homolog cyclope causes lethality in the germline and inhibition of cell
growth in somatic cells (248). The growth defect was observed in HEK293 cells overexpressing
COX VIc as well (249). These findings suggest that the functionality and the levels of COXVIc
protein play an important role in mitochondrial energetics. Follow up studies need to be done, but
the findings presented here suggest that COX VIc plays a role in regulating COX activity. Further,
the addition of MNRR1 to COX causes the spectra of COX to shift from 412 nm to 436 nm,
indicating a structural change in the heme vicinity of the core subunit. It would be interesting to
see if the COX VIc subunit is flexible upon MNRR1 binding through in silico structure prediction
of MNRR1 and molecular dynamics and docking simulations with COX and MNRR1.
The protrusion of COX VIc into the IMS is near the cytc binding pocket (Figure 17E). We
assessed the effect of MNRR1 phosphorylation on the electron transfer and binding between cytc
and COX using ruthenium labeled cytc and tissue-purified COX in an in vitro system. We observed
that the presence of neither WT or Y99E MNRR1 changed the electron transfer from cytc to COX
from basal conditions (Figure 18A) but the addition of Y99E did increase the stability of the cytcCOX complex at increasing ionic strength compared to WT and basal measurements. This finding
is supported by a study that shows the knockout of MNRR1 destabilizes cytc (227).
Research assessing the function of MNRR1 in PD is relatively new in the field. Upon
literature review for this portion of the project, I noted that research involving MNRR1 and PD, or
just PD itself, is fairly incohesive between researchers. One issue is that obtaining primary
dopaminergic neurons from patients is not practical and primary neurons are notoriously difficult
to culture, so the gold standard cell line has become neuroblastoma SH-SY5Y cells, which are
immortalized, have DA neuronal features, and are much easier to culture. Meta-analysis of
literature done by others suggests that SH-SY5Y differentiation does not significantly affect the
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cell line function (250). Another issue that I noted is that the induction of PD using MPP+ varies
in a broad range of concentrations and incubation times of treatment. Yet another issue comes
from the use of peripheral tissue cells instead of a neuronal cell line. The metabolism between
the brain and peripheral tissues is quite different, and it should be expected that not all findings
in commonly used cells such as HEK293 and HeLa cells will recapitulate neuronal physiology.
Standardization of models in PD research using human tissues will greatly help reproducibility in
the field and allow for more streamlined research of the disease.
A good portion of MNRR1 PD research has been done in D. melanogaster. It should be
noted that this protein shares considerable sequence overlap with both human MNRR1 and
CHCHD10. This may have caused some of the observations noted in CG5010 KO flies overexpressing human MNRR1 but not co-expressing human CHCHD10. Tio et al., 2017 (207), saw
an increase in H2O2 production, death of DA neurons, and reduced lifespan in flies overexpressing human WT MNRR1 compared to the EV control.
Despite these difficulties, we tested both WT and PD-associated T61I MNRR1 in both
basal and MPP+ treated conditions in WT SH-SY5Y cells. Our data show that overexpression of
T61I MNRR1 causes mitochondrial OCR to increase in basal conditions compared to WT (data
not shown). This finding conflicts with another study, which showed no difference after
overexpression of the T61I mutant in the same cell line (228). However, it should be noted that
this publication does not list the cell culture conditions or details of their Seahorse Bioanalyzer
protocol. The number of cells plated for the assay, as well as the type of medium used, can have
effects that could explain the discrepancy in results. One common example of variation would be
in the media in which the OCR reading was performed. In many studies, intact respiration is
performed in galactose medium, which forces the cells into aerobic respiration. However,
neuronal cells perform oxidative metabolism of glucose and glucose is a main sugar source of
ATP used by the brain (251), which would explain the difference in results. In any case, there was
no significant difference shown in OCR when the cells were treated with MPP+. OCR in WT SH-
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SY5Y cells could not be rescued by the overexpression of the C-S (nuclear localization) mutant
or the expression of Y99E MNRR1 (Figure 20B). These data suggest that the overexpression of
MNRR1 is not sufficient to rescue the oxygen defect with complex I inhibition by MPP+ in neuronal
cells.
In WT SH-SY5Y cells expressing our MNRR1 ORE luciferase reporter with the T61I
mutation shows a difference in transcriptional activation from WT MNRR1 cells in vehicle and
MPP+ treated conditions. In vehicle treated T61I cells, the MNRR1 ORE reporter is activated on
the level of the positive control C-S transcriptionally active mutant of MNRR1.When the cells are
treated with MPP+, a decrease in transcriptional activity occurs, returning to WT levels. These
data suggest that the T61I mutant is transcriptionally defective during stress and may contribute
to a PD phenotype through its nuclear function. It would be interesting to test the interaction
between RBPJk to determine if the mechanism of the reduced capacity of T61I MNRR1 to activate
transcription is based on an inability to bind RBPJk.
Protein level of MNRR1’s isoform, CHCHD10, is affected by the presence of the T61I
mutant in WT SH-SY5Y cells. In the same MPP+ treated T61I cells where transcriptional
repression is observed, the levels of CHCHD10 increase. CHCHD10 has been shown to be a
transcriptional repressor of the ORE (115). One hypothesis is that the increase in CHCHD10
levels observed in these cells is nuclear specific. This can be tested by isolating mitochondria and
nuclei from cells in the same experimental conditions as described Figure 22. If the increase in
CHCHD10 is localized to the nucleus, it is likely that this increase is resultant in ORE
transcriptional repression.
The difference in FLAG-tagged and endogenous MNRR1 protein levels between the
vehicle and MPP+ treated T61I cells could be due to alternating levels of YME1L1 between
treatments. In vehicle treated T61I cells, where the T61I mutant protein level is low compared to
WT controls, there is a marked increase in YME1L1 levels. Because YME1L1 targets MNRR1 in
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the mitochondria, an increase in the protease could lead to turnover of the PD-associated mutant
and endogenous MNRR1. The reduced levels of MNRR1 in the presence of T61I may have to do
with the ability of the mutant to oligomerize with WT MNRR1, causing the protein to precipitate in
the mitochondrial (252). This would likely turn on the mtUPR, at least in the IMS, causing the
increase in YME1L1 to respond to proteotoxic stress in the presence of the T61I mutant. When
the cells are challenged with MPP+, the levels of YME1L1 decrease, which matches the
repression of the ORE in the nucleus and the stabilization of both endogenous and T61I MNRR1.
Given what our lab has shown regarding the involvement of MNRR1 in the mtUPR response, a
second marker was assessed for mtUPR induction in the presence of the T61I mutant. The
increase in Hsp60 protein in the presence of the T61I mutant and stress challenge suggests that
the mtUPR is induced.
The difference between the IMS and matrix mtUPR markers is an interesting observation.
It is possible that the T61I mutant causes a compartment specific induction of the mtUPR without
further stress challenge. However, upon further stress induction, we note an induction of the
matrix mtUPR. It has been suggested in literature that over activation of mtUPR may be a
contributing factor to disease pathogenesis and mitochondrial dysfunction accompanying ageing
(253). In fact, the over-activation of mtUPR contributes to neurodegenerative diseases, including
PD (170), however this has yet to be studied in a compartment-specific manner. The T61I mutant
may induce mtUPR in the IMS which in turn causes the pathway to be chronically activated in the
heterozygous cells. This hypothesis warrants further investigation to fully determine the
dysfunction occurring in T61I expressing cells.
Overall, this project was able to add knowledge of the function of MNRR1 in the
mitochondria and the nucleus. MNRR1 has been shown to participate in mitochondria-nuclear
crosstalk by participating in the mtUPR. The findings added to the working model of the Grossman
lab, showing that MNRR1 regulates mitochondrial function based on its phosphorylation status
(Figure 17-19). The preferential binding between phosphorylated and unphosphorylated MNRR1
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dictates the ability for YME1L1 to preferentially degrade the phosphorylated pool of mitochondrial
MNRR1, allowing the pool of Bcl-xL associated MNRR1 to inhibit apoptosis. When MNRR1 is
interacting with COX, it may be doing so through a subunit of unknown function, COX VIc. This
finding provides molecular insights to a potential function of the subunit in the regulation of the
complex activity. The role of MNRR1 in PD is still unclear and much more work needs to be done
as this project goes forward. This thesis project does show that MNRR1 is involved mtUPR, finetuning COX function, and an unbalanced or chronic mtUPR response, which can be further
studied in the context of PD.
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CHAPTER IV: MATERIALS AND METHODS
4.1 Reagents
Antibodies. Actin (catalog no. 12748), GAPDH (3683), tubulin (9099), HSP60 (46611),
NDUFS3 (15066-1-AP), DRBP76 (19887-1-AP), COX IV (11242-1-AP), and LONP1 (56266)
antibodies were purchased from Cell Signaling Technologies. MNRR1 (19424-1-AP), p62 (184201-AP), and YME1L1 (11510-1-AP) antibodies from Proteintech. FLAG (A8592) antibody was
purchased from Sigma.
Chemicals. Chemicals used in this study include doxycycline (sc-337961) and
cycloheximide (sc-3508) purchased from Santa Cruz Biotechnology. MPP+ (ab144783) was
purchased from Abcam. Dual luciferase assay kit (E1910) was purchased from Promega. Thermo
Fisher Mitochondrial Isolation Kit for Cultured Cells (Thermo Fisher Scientific, 89874).
4.2 Cell lines
HEK 293 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) (HyClone,
SH30243), with 10% FBS (Sigma Aldrich, F2442), 1% penicillin-streptomycin (P/S) (Gibco,
15140-122). To generate an MNRR1 KO, HEK 293 cells were transfected with a human MNRR1
CRISPR/Cas9 KO plasmid pair (Santa Cruz Biotechnology, sc-412127 and sc-412127-HDR),
followed by selection for puromycin-resistant colonies and clones. Knockout was confirmed by
immunoblotting. YME1L1 WT and KO MEF cells were a gift from Dr. Thomas Langer, Institute of
Genetics, University of Cologne. The medium for MEFs has been described previously (254) . To
generate YME1L1 KD in HEK 293, cells were transfected with YME1L1 siRNA (and scramble for
control) and then grown in DMEM with 10% FBS and 1% P/S for 48 hours. SH-SY5Y cells were
maintained in DMEM/F-12 with L-glutamine (Corning, 10-090-CV) with 10% FBS (Sigma Aldrich,
F2442), 1% P/S (Gibco, 15140-122).
All cells were cultured in a humidified incubator at 37 °C. The normoxia-hypoxia
experiments were performed as described previously (147).
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4.3 Plasmids
All MNRR1 mammalian expression plasmids were cloned into pCI-Neo vector with a cterminal 3× Flag tag. The WT, Y99E, Y99F, and C-S MNRR1 expression plasmids have been
described previously (113, 147). The T61I MNRR1 expression vector was constructed by
Genscript. The Ubiquitin-HA expression vector was a gift from Dr. Kezhong Zhang, Wayne State
University, Detroit, MI. The MNRR1 ORE luciferase reporter plasmid and the COX4I2 luciferase
reporter plasmids have been described previously (114, 147).
The c-terminal 6xhistidine tagged WT and Y99E MNRR1 were cloned into pET15b vector
by Dr. Siddhesh Aras, Wayne State University, Detroit, MI. The catalytic domain of YME1L1 in
pET15b was purchased from DNASU (HsCD00598203). The T61I MNRR1 expression plasmid in
pCold2 vector was a gift from Dr. Manabu Funayama, Juntendo University, Tokyo, Japan (227).
4.4 Transient transfection of cells
Cells were transfected with the indicated plasmids using TransFast transfection reagent
(Promega, Madison, WI) according to the manufacturer's protocol. A TransFast:DNA ratio of 2:1
in serum and antibiotic free medium was used. Following incubation at room temperature for ~15
min, the mixture was added to the cells. The plates were incubated overnight at 37 °C followed
by replacement with complete medium and further incubation for 48 hours.
4.5 Recombinant protein purification from E. coli
The catalytic domain of YME1L1 in pET15b (DNASU, HsCD00598203) was expressed in
BL21 (DE3) competent cells (NEB). Colonies were cultured in LB broth with 100 µg/ml ampicillin
(Sigma) at 37˙C until an OD600 between 0.5 and 0.6. Cells were induced with 1mM IPTG and
incubated at 37˙C for 16 hours with 240 rpm agitation. Cells were harvested by centrifugation at
3.5k rpm for 10 minutes. Bacterial pellets were suspended in 500 mM KCl, 20 mM Tris pH 7.9,
0.2% NP-40, 10% glycerol, 10 mM Imidazole with protease cocktail inhibitor (PIC) and 5 mM 2mercaptoethanol. Suspension was frozen at -20˚C overnight. Next day, thawed lysate was applied
to HIS-SelectÒ iLapÒ Column (Sigma, H9913) and purified per manufacturer protocol.
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MNRR1 bacterial expression vectors (WT and Y99E in pET15b), and T61I in pCold2) were
expressed in SHuffle® T7 Express lysY competent cells (NEB). Colonies were cultured in terrific
broth with 100 µg/ml ampicillin (Sigma) at 37˚C until an OD600 between 0.5 and 0.6. Cells were
induced with 100 µM IPTG and incubated at 16˚C overnight for 16 hours with 240 rpm agitation.
Cells were harvested by centrifugation at 4.5k rpm for 45 minutes. Bacterial pellets were
suspended in 500 mM NaCl, 40 mM NaH2PO4, and 5% glycerol with PIC and lysozyme. Cell
suspension was lysed using a French pressure cell press (AMINCO, American Instrument Co.,
Silver Spring, MD, USA). Lysate debris was pelleted at 12k RPM for one hour at 4˚C. Supernatant
was used to purify the HIS-tagged recombinant proteins using HIS-Select® Nickel Affinity gel
(Sigma) per manufacturer’s protocol with some modifications. The buffer wash step was repeated
2x to ensure all unbound proteins were exiting the column. A 25 mM and 50 mM imidazole wash
steps were included because this showed further removal of non-specific binding of contaminants.
The final elution was performed in 150 mM imidazole. Eluted protein was concentrated using
Amicron® Ultra 15 ml centrifugal filters (Millipore) and buffer exchanged to 20 mM Tris, pH 7.5,
100 mM NaCl. Protein aliquots were stored at -80˚C for long term storage.
4.6 In vitro protease assay
The assay to assess in vitro protease activity has been described elsewhere (255). Briefly,
recombinant HIS-tagged YME1L1 and MNRR1 (1 µg) each were combined in a reaction buffer
with final conditions of 50 mM Trish-HCl pH 8, 10 mM MgCl2, 25 mM NaCl, 25 mM imidazole,
0.001% NP40, and 0.5% glycerol in a 25 µl total volume. An ATP regeneration system was added
to the reactions as well with final concentrations of 50 mM pyruvate kinase, 4 mM ATP, and 80
µg/ml phosphoenolpyruvate. Reactions were incubated at 37˚C for one hour and reactions were
stopped via the addition of 4xSample Loading Buffer. Reactions were run on SDS-PAGE and the
presence of proteins was detected through immunoblotting. Control reactions included a MNRR1
only reaction, as well as tissue purified COX reactions, to show the specificity of the protease.
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4.7 Knockdown of YME1L1 in HEK 293 cells
YME1L1 siRNA was purchased from Santa Cruz Biotechnology, Inc. (sc-90696) as was
the scramble control. The siRNA was transfected according to manufacturer’s protocol.
4.8 Mitochondrial isolation and sub-fractionation
Cellular mitochondrial and nuclear fractions were isolated from cells with the Thermo
Fisher Mitochondrial Isolation Kit for Cultured Cells (Thermo Fisher Scientific, 89874) according
to the manufacturer’s protocol. Purity of fractions were determined using organelle specific
markers. Submitochondrial fractionation was performed by Dr. Siddhesh Aras (Wayne State
University, Detroit, MI) as described previously (256). These experiments are shown in Figure
12A and 12B and were included in the thesis as part of the MNRR1 turnover story to fully illustrate
the mechanism of MNRR1 activity during stress.
4.9 Reporter assays
Luciferase reporter assays were performed using the dual luciferase reporter assay kit
(E1910, Promega) as described previously (114, 147). Transfection efficiency was normalized
with the co-transfected pRLSV40 Renilla luciferase expression plasmid.
4.10 In vitro COX activity
Purified bovine liver COX was a gift from the lab of Dr. Maik Hüttemann, Wayne State
University, Detroit, MI. The purified complex was diluted to 3 µM and cardiolipin (Sigma, St. Louis,
MO, USA) was added at a 40:1 cardiolipin:COX molar ratio. COX was dialyzed using a 12K-14K
molecular weight cut-off membrane in measurement buffer containing 10 mM K-HEPES pH 7.4,
40 mM KCl, 1% Tween-20, and 0.2 mM ATP overnight at 4˚C overnight to remove bound collate,
an artifact from purification, and replenish cardiolipin, as described in Lee et. al. (241).
Oxygen consumption was measured using a Clark-type oxygen electrode (Oxygraph
System, Hasentech, Pentney, UK) at a final concentration of 30 nM COX in 220 µl measurement
buffer. Ascorbate (20 mM) was added to donate electrons to cytc. Basal oxygen consumption was
measured and then purified cytc (30 nM) (Sigma, C3131) was injected into chamber and oxygen
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consumption was measured. Next, buffer, WT, Y99E, or T61I recombinant MNRR1 was injected
for final oxygen consumption measurement. Measurements were performed at 25˚C. Oxygen
consumption was recorded and analyzed using Hansatech Oxygraph software. COX activity was
determined as oxygen consumed per minute (min-1).
4.11 Chemical cross-linking and mass spectrometry
Purified and dialyzed bovine liver COX and recombinant WT MNRR1 were used in the
cross-linking experiment. A 5:1 molar ratio of MNRR1:COX was used in the presence of 0.25 mM
DSS in a buffer containing 100 mM Na2PO4, 0.15 M NaCl, pH 7.5. Reactions were incubated on
ice for 2 hours. Reactions were quenched using 45 mM Tris-HCl, pH 7.5 for 20 minutes on ice.
Identification of cross-linking of recombinant WT MNRR1 to COX was performed with
immunoblotting and membrane bands were submitted for mass spectrometry at the Wayne State
University Proteomics Core (Detroit, MI, USA) for peptide identification.
4.12 Absorbance spectra of COX
The absorbance spectrum of bovine liver COX in the absence and presence of
recombinant WT MNRR1 (my preparation) was determined by Dr. Sachiko Yanagisawa (Hyogo
University, Kakogawa, Japan). Oxidized COX spectra was measured from 350-700 nm using UVVIS absorbance spectroscopy. The molar ratio of recombinant WT MNRR1:COX was 2:1.
4.13 In vitro electron transfer and cytc:COX binding measurements
Assays were performed by Marti Scharlau in the laboratory of Dr. Francis Millett
(University of Arkansas, Fayetteville, AR, USA) with materials sent by me as described elsewhere
(243). Briefly, flash photolysis and transient absorbance spectroscopy were performed to
determine electron transfer rate and binding between ruthenium labeled cytc and bovine heart
COX. The dissociation rate constant kd and the equilibrium dissociation constant KD = kd/kf were
measured from 20 to 60 mM NaCl, and the formation rate constant kf was measured from 40 to
110 mM NaCl. See Scheme 1 below (243).
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Scheme 1

4.14 Co-immunoprecipitation and immunoblotting
Co-immunoprecipitation and immunoblotting were performed as described previously
using specific antibodies (113, 114, 147). Primary antibodies were used at 1:1000 dilution and
secondary antibodies were used at 1:5000 dilution, unless otherwise specified. The pulldown with
the Y99E and Y99F MNRR1 mutants for Bcl-xL interaction was performed by Dr. Siddhesh Aras,
Wayne State University, Detroit, MI.
4.15 Intact cellular oxygen consumption
Cellular oxygen consumption was measured with a Seahorse XFe24 Bioanalyzer. Cells
were plated at a concentration of 30,000 per well for transfection 72 hrs before assay (see
Material and Methods section 4.4 for transfection methods). On the day of assay, plates were
pre-treated with 250 µM MPP+ or DMSO (vehicle) 7 hours before assay (Pilot assay for optimal
MPP+ concentration was done by Dr. Siddhesh Aras, Wayne State University, Detroit, MI).
Basal oxygen consumption reads were performed according to the manufacturer's instructions
in SH-SY5Y cell culture media.
4.16 Statistical analysis
Statistical analyses were performed with MSTAT version 6.1.1 (N. Drinkwater, University
of Wisconsin, Madison, WI). The two-sided Wilcoxon rank-sum test was applied to determine
statistical significance for p-values. Data were considered statistically significant with p <0.05.
4.17 Publications
Chapter I contains materials published in the following reviews:
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(111) L. I. Grossman et al., MNRR1, a Biorganellar Regulator of Mitochondria. Oxid Med
Cell Longev 2017, 6739236 (2017).
(99) S. Gladyck, S. Aras, M. Huttemann, L. I. Grossman, Regulation of COX Assembly
and Function by Twin CX9C Proteins-Implications for Human Disease. Cells 10,
(2021).
Chapters II – IV contains materials published in the following research article:
(58) S. Aras et al., Mitochondrial Nuclear Retrograde Regulator 1 (MNRR1) rescues the
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ABSTRACT
MNRR1: UNDERSTANDING THE ROLE OF A NOVEL MITOCHONDRIAL-NUCLEAR
REGULATOR
by
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Mitochondria are complex organelles that generate most of the energy required to sustain
life and function in metabolic and signaling pathways required to maintain cellular homeostasis.
MNRR1 (mitochondrial nuclear retrograde regulator 1 or CHCHD2) is a small, bi-organellar twin
CX9C protein that is emerging as an important regulator of mitochondrial function, apoptosis, and
cellular stress by participating in mitochondrial-nuclear crosstalk. Our lab has previously shown
that in the mitochondria, MNRR1 regulates complex IV (Cytochrome c oxidase or COX) and is
able to finetune the oxidase function through phosphorylation status. We have also shown that
during stress, mitochondrial MNRR1 levels deplete, while nuclear levels increase. MNRR1 in the
nucleus activates transcription of genes containing an oxygen responsive element (ORE) in their
promoter. Additionally, others have shown that MNRR1 acts as an anti-apoptotic molecule
through interaction with Bcl-xL. Here we report that a protease responsible for MNRR1
degradation in the mitochondria is YME1L1, a key protease for mitochondrial quality control and
for the mitochondrial unfolded protein response (mtUPR). Through this association, the role of
MNRR1 in mtUPR was investigated and determined to be a transcriptional activator during
mtUPR through its nuclear function. We also report that MNRR1 likely binds near the cytochrome
c (cytc) binding pocket located on COX via interaction with COX Vic and that this interaction
increases the stability of the cytc:COX when MNRR1 is phosphorylated. We also show that
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unphosphorylated MNRR1 preferentially binds to Bcl-xL compared to phosphorylated. Taken
together, the findings presented here suggest that phosphorylation of MNRR1 plays a role in
finetuning its mitochondrial function. The proposed model is that at the inner mitochondrial
membrane, YME1L1 targets the MNRR1 bound to COX during stress to attenuate the production
of energy, while the Bcl-xL bound MNRR1 pool remains to prevent apoptosis. At the same time,
blocked intermembrane space import results in the accumulation of MNRR1 in the nucleus, to
activate a transcriptional response in the ORE. Mutations in MNRR1 are associated with
Parkinson’s disease (PD), yet the pathogenic mechanism is not clear. Here, we report that
induction of PD in a cell culture model shows that protein levels of MNRR1 and other mtUPR
proteins are affected in the presence of the T61I mutant. It was also determined that the PDassociated mutation T61I is defective for nuclear function as a transcription factor in MPP+ treated
cells.
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